A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent

Novel molecularly targeted agents (MTAs) have emerged as valuable alternatives or complements to traditional cytotoxic agents in the treatment of cancer. Clinicians are combining cytotoxic agents with MTAs in a single trial to achieve treatment synergism and better outcomes for patients. An importan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the Royal Statistical Society 2015-01, Vol.64 (1), p.215-229
Hauptverfasser:	Riviere, M.-K., Yuan, Y., Dubois, F., Zohar, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Applied statistics Bayesian analysis Bayesian method Biochemistry, Molecular Biology Cancer Clinical trials Combination Complement Cytotoxicity Cytotoxins Dosage Dose finding Dose response relationship Drug combinations Effectiveness Health outcomes Life Sciences Logistics Maximum tolerated dose Medical research Molecularly targeted agent Optimization Patients Phase I-II Probability Regression Regression analysis Response rates Simulations Statistical analysis Studies Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!